Diagnóstico del síndrome de falla cardíaca. Recomendaciones basadas en la evidencia para la guía de falla cardíaca de Colombia

Juan Manuel Senior, Edison Muñoz-Ortiz, James Samir Díaz- Betancur

Resumen


Introducción: para el diagnóstico de falla cardíaca se requiere el hallazgo de los síntomas y signos de la enfermedad con evidencia objetiva de una anomalía estructural o funcional del corazón.

Metodología: para crear la guía de práctica clínica (GPC) basada en la evidencia se siguieron los pasos definidos en la Guía Metodológica para la Elaboración de Guías de Práctica Clínica con Evaluación Económica en el Sistema General de Seguridad Social en Salud del Ministerio de Salud y Protección Social de Colombia.

Resultados: se establecen las recomendaciones de diagnóstico. Conclusión: el diagnóstico de falla cardíaca se establece con el cuadro clínico en una proporción importante de pacientes, junto con la información obtenida del electrocardiograma y la radiografía de tórax. En algunos casos dudosos se deben utilizar otras herramientas diagnósticas que permitan descartarla con un grado bajo de incertidumbre.


Palabras clave


Diagnóstico; Guía; Insuficiencia cardíaca

Texto completo:

PDF

Referencias


(1.) McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 Jul;33(14):1787-847. DOI 10.1093/eurheartj/ehs104. Erratum in: Eur Heart J. 2013 Jan;34(2):158.

(2.) Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the rican College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct;62(16):e147-239. DOI 10.1016/j.jacc.2013.05.019.

(3.) Balion C, Santaguida PL, Hill S, Worster A, McQueen M, Oremus M, et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evid Rep Technol Assess (Full Rep). 2006 Sep;(142):1-147.

(4.) Balion C, Don-Wauchope A, Hill S, Santaguida PL, Booth R, Brown JA, et al. Use of Natriuretic Peptide Measurement in the Management of Heart Failure [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013. (Comparative Effectiveness Reviews, No. 126). Disponible en: https://www.effectivehealthcare.ahrq.gov/ehc/products/328/1754/heart-failure-natriuretic-peptidereport-131119.pdf

(5.) Barcarse E, Kazanegra R, Chen A, Chiu A, Clopton P, Maisel A. Combination of B-type natriuretic peptide levels and non-invasive hemodynamic parameters in diagnosing congestive heart failure in the emergency department. Congest Heart Fail. 2004 Jul-Aug;10(4):171-6.

(6.) Maisel AS, Clopton P, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J. 2004 Jun;147(6):1078-84.

(7.) Knudsen CW, Riis JS, Finsen AV, Eikvar L, Müller C, Westheim A, et al. Diagnostic value of a rapid test for B-type natriuretic peptide in patients presenting with acute dyspnoe: effect of age and gender. Eur J Heart Fail. 2004 Jan;6(1):55-62.

(8.) Knudsen CW, Omland T, Clopton P, Westheim A, Abraham WT, Storrow AB, et al. Diagnostic value of B-Type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med. 2004 Mar;116(6):363-8.

(9.) Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003 Aug;42(4):728-35.

(10.) Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, et al. Bedside B- Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003 Jun;41(11):2010-7.

(11.) McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003 Mar;10(3):198-204.

(12.) Villacorta H, Duarte A, Duarte NM, Carrano A, Mesquita ET, Dohmann HJ, Et al. The role of B-type natriuretic peptide in the diagnosis of congestive heart failure in patients presenting to an emergency department with dyspnea. Arq Bras Cardiol. 2002 Dec;79(6):569-72, 564-8. English, Portuguese.

(13.) Logeart D, Saudubray C, Beyne P, Thabut G, Ennezat PV, Chavelas C, et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol [Internet]. 2002 Nov[cited 2016 Jul 19];40(10):[1794-800]. Available from: http://content.onlinejacc.org/article.aspx?articleid=1130481

(14.) McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002 Jul;106(4):416-22.

(15.) Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of Btype natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002 Jul;347(3):161-7.

(16.) Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002 Jan;39(2):202-9.

(17.) Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001 Feb;37(2):379-85.

(18.) Wu AH, Omland T, Duc P, McCord J, Nowak RM, Hollander JE, et al. The effect of diabetes on B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the Breathing Not Properly Multinational Study. Diabetes Care. 2004 Oct;27(10):2398-404.

(19.) Ray P, Arthaud M, Lefort Y, Birolleau S, Beigelman C, Riou B, et al. Usefulness of B-type natriuretic peptide in elderly patients with acute dyspnea. Intensive Care Med. 2004 Dec;30(12):2230-6.

(20.) Choi S, Park D, Lee S, Hong Y, Kim S, Lee J. Cut-off values of B-type natriuretic peptide for the diagnosis of congestive heart failure in patients with dyspnoea visiting emergency departments: a study on Korean

patients visiting emergency departments. Emerg Med J. 2007 May;24(5):343-7.

(21.) Coste J, Jourdain P, Pouchot J. A gray zone assigned to inconclusive results of quantitative diagnostic tests: Application to the use of brain natriuretic peptide for diagnosis of heart failure in acute dyspneic patients. Clin Chem. 2006 Dec;52(12):2229-35.

(22.) Sanz MP, Borque L, Rus A, Vicente B, Ramírez Y, Lasa L. Comparison of BNP and NT-proBNP assays in the approach to the emergency diagnosis of acute dyspnea. J Clin Lab Anal. 2006;20(6):227-32.

(23.) Chung T, Sindone A, Foo F, Dwyer A, Paoloni R, Janu MR, et al. Influence of history of heart failure on diagnostic performance and utility of B-type natriuretic peptide testing for acute dyspnea in the emergency department. Am Heart J. 2006 Nov;152(5):949-55.

(24.) Collins SP, Lindsell CJ, Peacock WF, Hedger VD, Askew J, Eckert DC, et al. The combined utility of an S3 heart sound and B-type natriuretic peptide levels in emergency department patients with dyspnea. J Card Fail. 2006 May;12(4):286-92.

(25.) Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006 May;151(5):999-1005.

(26.) Chenevier-Gobeaux C, Claessens YE, Voyer S, Desmoulins D, Ekindjian OG. Influence of renal function on N-terminal pro-brain natriuretic peptide (NTproBNP) in patients admitted for dyspnoea in the Emergency Department: comparison with brain natriuretic peptide (BNP). Clin Chim Acta. 2005 Nov;361(1-2):167-75.

(27.) Knudsen CW, Omland T, Clopton P, Westheim A, Wu AH, Duc P, et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005 Sep;46(5):838-44.

(28.) Steg PG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest. 2005 Jul;128(1):21-9.

(29.) Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart. 2005 May;91(5):606-12.

(30.) Ray P, Arthaud M, Birolleau S, Isnard R, Lefort Y, Boddaert J, et al. Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older. J Am Geriatr Soc. 2005 Apr;53(4):643-8.

(31.) Alibay Y, Beauchet A, El Mahmoud R, Schmitt C, Brun-Ney D, Benoit MO, et al. Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea. Biomed Pharmacother. 2005 Jan-Feb;59(1-2):20-4.

(32.) Gorissen C, Baumgarten R, de Groot M, van Haren E, Kragten H, Leers M. Analytical and clinical performance of three natriuretic peptide tests in the emergency room. Clin Chem Lab Med. 2007;45(5):678-84.

(33.) Arques S, Roux E, Sbragia P, Pieri B, Gelisse R, Luccioni R, et al. Usefulness of bedside tissue Doppler echocardiography and B-type natriuretic peptide (BNP) in differentiating congestive heart failure from noncardiac cause of acute dyspnea in elderly patients with a normal left ventricular ejection fraction and permanent, nonvalvular atrial fibrillation: insights from a prospective, monocenter study. Echocardiography. 2007 May;24(5):499-507.

(34.) Wang HK, Tsai MS, Chang JH, Wang TD, Chen WJ, Huang CH. Cardiac ultrasound helps for differentiating the causes of acute dyspnea with available Btype natriuretic peptide tests. Am J Emerg Med. 2010 Nov;28(9):987-93. DOI 10.1016/j.ajem.2009.05.019.

(35.) Chenevier-Gobeaux C, Guerin S, André S, Ray P, Cynober L, Gestin S, et al. Midregional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department: a comparison with B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem. 2010 Nov;56(11):1708-17. DOI 10.1373/clinchem.2010.145417.

(36.) Boldanova T, Noveanu M, Breidthardt T, Potocki M, Reichlin T, Taegtmeyer A, et al. Impact of history of heart failure on diagnostic and prognostic value of BNP: results from the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) study. Int J Cardiol. 2010 Jul;142(3):265-72. DOI 10.1016/j.ijcard.2008.12.214.

(37.) Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010 May;55(19):2062-76. DOI 10.1016/j.jacc.2010.02.025.

(38.) Lokuge A, Lam L, Cameron P, Krum H, de Villiers S, Bystrzycki A, et al. B-type natriuretic peptide testing and the accuracy of heart failure diagnosis in the emergency department. Circ Heart Fail. 2010 Jan;3(1):104-10. DOI 10.1161/CIRCHEARTFAILURE.109.869438.

(39.) Potocki M, Breidthardt T, Reichlin T, Hartwiger S, Morgenthaler NG, Bergmann A, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med. 2010 Jan;267(1):119-29. DOI 10.1111/j.1365-2796.2009.02135.x.

(40.) Kevin Rogers R, Stehlik J, Stoddard GJ, Greene T, Collins SP, Peacock WF, et al. Adjusting for clinical covariates improves the ability of B-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: a sub-study of HEARD-IT. Eur J Heart Fail. 2009 Nov;11(11):1043-9. DOI 10.1093/eurjhf/hfp127. Erratum in: Eur J Heart Fail. 2010 May;12(5):524-5.

(41.) Pahle AS, Sørli D, Omland T, Knudsen CW, Westheim A, Wu AH, et al. Impact of systemic hypertension on the diagnostic performance of B-type natriuretic peptide in patients with acute dyspnea. Am J Cardiol. 2009 Oct;104(7):966-71. DOI 10.1016/j.amjcard.2009.05.039.

(42.) Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart. 2009 Sep;95(18):1508-13. DOI 10.1136/hrt.2009.170696.

(43.) Rogers RK, Stoddard GJ, Greene T, Michaels AD, Fernandez G, Freeman A, et al. Usefulness of adjusting for clinical covariates to improve the ability of B-type natriuretic peptide to distinguish cardiac from noncardiac dyspnea. Am J Cardiol. 2009 Sep;104(5):689-94. DOI 10.1016/j.amjcard.2009.04.043.

(44.) Noveanu M, Breidthardt T, Cayir S, Potocki M, Laule K, Mueller C. B-type natriuretic peptide-guided management and outcome in patients with obesity and dyspnea--results from the BASEL study. Am Heart J. 2009 Sep;158(3):488-95. DOI 10.1016/j.ahj.2009.05.033.

(45.) Shah KB, Kop WJ, Christenson RH, Diercks DB, Kuo D, Henderson S, et al. Natriuretic peptides and echocardiography in acute dyspnoea: implication of elevated levels with normal systolic function. Eur J Heart Fail. 2009 Jul;11(7):659-67. DOI 10.1093/eurjhf/hfp075.

(46.) Gruson D, Thys F, Ketelslegers JM, Pasquet A, Delvau N, Deneys V, et al. Multimarker panel in patients admitted to emergency department: a comparison with reference methods. Clin Biochem. 2009 Feb;42(3):185-8. DOI 10.1016/j.clinbiochem.2008.08.078.

(47.) Shah KB, Kop WJ, Christenson RH, Diercks DB, Kuo D, Henderson S, et al. Lack of diagnostic and prognostic utility of circulating plasma myeloperoxidase concentrations in patients presenting with dyspnea. Clin Chem. 2009 Jan;55(1):59-67. DOI 10.1373/clinchem.2008.108159.

(48.) Gruson D, Rousseau MF, Ahn S, Van Linden F, Thys F, Ketelslegers JM, et al. Accuracy of N-terminalpro-atrial natriuretic peptide in patients admitted to emergency department. Scand J Clin Lab Invest. 2008;68(5):410-4. DOI 10.1080/00365510701810605.

(49.) Parrinello G, Paterna S, Di Pasquale P, Torres D, Fatta A, Mezzero M, et al. The usefulness of bioelectrical impedance analysis in differentiating dyspnea due to decompensated heart failure. J Card Fail. 2008 Oct;14(8):676-86. DOI 10.1016/j.cardfail.2008.04.005.

(50.) Chenevier-Gobeaux C, Delerme S, Allo JC, Arthaud M, Claessens YE, Ekindjian OG, et al. B-type natriuretic peptides for the diagnosis of congestive heart failure in dyspneic oldest-old patients. Clin Biochem. 2008 Sep;41(13):1049-54. DOI 10.1016/j.clinbiochem.2008.05.012.

(51.) deFilippi CR, Seliger SL, Maynard S, Christenson RH. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem. 2007 Aug;53(8):1511-9.

(52.) Havelka EG, Rzechula KH, Bryant TO, Anneken SM, Kulstad EB. Correlation between impedance cardiography and B-type natriuretic peptide levels in dyspneic patients. J Emerg Med. 2011 Feb;40(2):146-50. DOI 10.1016/j.jemermed.2008.01.019.

(53.) Gruson D, Ketelslegers JM, Verschuren F, Thys F. Headto-head comparison of the prohormone proBNP1-108 with BNP and Nt-proBNP in patients admitted to emergency department. Clin Biochem. 2012 Feb;45(3):249-52. DOI 10.1016/j.clinbiochem.2011.12.009.

(54.) Ro R, Thode HC Jr, Taylor M, Gulla J, Tetrault E, Singer AJ. Comparison of the diagnostic characteristics of two B-type natriuretic peptide point-of-care devices. J Emerg Med. 2011 Dec;41(6):661-7. DOI 10.1016/j.jemermed.2010.10.025.

(55.) Arenja N, Reichlin T, Drexler B, Oshima S, Denhaerynck K, Haaf P, et al. Sensitive cardiac troponin in the diagnosis and risk stratification of acute heart failure. J Intern Med. 2012 Jun;271(6):598-607. DOI 10.1111/j.1365-2796.2011.02469.x.

(56.) National Clinical Guideline Centre (UK). Acute Heart Failure: Diagnosing and Managing Acute Heart Failure in Adults [Internet]. London: National Institute for Health and Care Excellence (UK); 2014 [cited 2015 Nov]. Available from: https://www.nice.org.uk/guidance/cg187

(57.) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med. 1992 Sep;327(10):685-91. Erratum in: N Engl J Med 1992 Dec;327(24):1768.

(58.) Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep;327(10): 669-77.

(59.) Smith H, Pickering RM, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. BMJ. 2000 Apr;320(7239):906-8.

(60.) Hutcheon SD, Gillespie ND, Struthers AD, McMurdo ME. B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. Age Ageing. 2002 Jul;31(4):295-301.

(61.) Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care. 2003 Jul;26(7):2081-7.

(62.) Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study. Am J Med. 2004 Apr;116(8):509-16.

(63.) Hedberg P, Lönnberg I, Jonason T, Nilsson G, Pehrsson K, Ringqvist I. Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women. Am Heart J. 2004 Sep;148(3):524-9.

(64.) Lobos Bejarano JM, Horrillo García C, González-González AI, Castellanos Rodríguez A, Díaz Sánchez S, Castellanos Maroto J, et al. [Validity and usefulness of Btype natriuretic peptide (BNP) for early detection of left ventricular dysfunction in high-risk patients in primary care]. Aten Primaria. 2012 Jan;44(1):13-9. DOI 10.1016/j.aprim.2010.12.009.

(65.) Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK. Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart. 2004 Aug;90(8):866-70.

(66.) Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general

population. J Am Coll Cardiol. 2003 Jan;41(1): 113-20.

(67.) Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation. 2004 Jun;109(25):3176-81.

(68.) Ledwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013 Jul;310(1):66-74. DOI 10.1001/jama.2013.7588.

(69.) Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart. 2004 Mar;90(3):297-303.

(70.) Betti I, Castelli G, Barchielli A, Beligni C, Boscherini V, De Luca L, et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail. 2009 Jun;15(5):377-84. DOI 10.1016/j.cardfail.2008.12.002.

(71.) Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J. 2005 Nov;26(21):2269-76.

(72.) Karamitsos TD, Neubauer S. Cardiovascular magnetic resonance in heart failure. Curr Cardiol Rep. 2011 Jun;13(3):210-9. DOI 10.1007/s11886-011-0177-2.

(73.) Yoshida A, Ishibashi-Ueda H, Yamada N, Kanzaki H, Hasegawa T, Takahama H, et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail. 2013 Feb;15(2):166-75. DOI 10.1093/eurjhf/hfs206.

(74.) Bart BA, Shaw LK, McCants CB Jr, Fortin DF, Lee KL, Califf RM, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997 Oct;30(4):1002-8.

(75.) Lim MJ, White CJ. Coronary angiography is the gold standard for patients with significant left ventricular dysfunction. Prog Cardiovasc Dis. 2013 Mar-Apr;55(5):504-8. DOI 10.1016/j.pcad.2013.01.003.

(76.) McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A,et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol. 2013 Feb;29(2):168-81. DOI 10.1016/j.cjca.2012.10.007.

(77.) Melo RM, Melo EF, Biselli B, Souza GE, Bocchi EA. Clinical usefulness of coronary angiography in patients with left ventricular dysfunction. Arq Bras Cardiol. 2012 May;98(5):437-41.

(78.) Flaherty JD, Rossi JS, Fonarow GC, Nunez E, Stough WG, Abraham WT, et al. Influence of coronary angiography on the utilization of therapies in patients with acute heart failure syndromes: findings from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2009 Jun;157(6):1018-25. DOI 10.1016/j.ahj.2009.03.011.

(79.) Braga JR, Tu JV, Austin PC, Chong A, You JJ, Farkouh ME, et al. Outcomes and care of patients with acute heart failure syndromes and cardiac troponin elevation. Circ Heart Fail. 2013 Mar;6(2):193-202. DOI 10.1161/CIRCHEARTFAILURE.112.000075.


Resumen : 958 PDF : 813

Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Copyright (c) 2017 Iatreia

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

Esta publicación hace parte del Sistema de Revistas de la Universidad de Antioquia
¿Quieres aprender a usar el Open Journal system? Ingresa al Curso virtual
Este sistema es administrado por el Programa Integración de Tecnologías a la Docencia
Universidad de Antioquia
Powered by Public Knowledge Project